Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We RADNOR, Pa.–(BUSINESS IV Ganaxolone in Pediatric Super-Refractory Status Epilepticus: Two Case Presentations.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

FloridaMarijuana.net

JUNE 27, 2018

The study’s data showed that “Cannabis significantly reduced ratings of depression, anxiety, and stress.” Participants in the study recorded their personal experience when using cannabis for their depression and other mental conditions such as anxiety and stress; scientists were able to use data collected from the app to analyze the results.

Treatment 100

Treatment Marijuana Conditions Data 100

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Info

MARCH 2, 2019

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. Epilepsy is usually diagnosed after patients have experienced a series of seizures. CONVENTIONAL TREATMENT. Treatment includes surgery and nutritional and lifestyle changes.

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Veriheal

SEPTEMBER 23, 2021

Fortunately, one such man, Levi Barker, provided us with some much-needed insight into what the substance is, how it is used in treatment, and more. Many of us have more in our minds than we need… Veriheal: Can you walk us through a typical iboga treatment? One could even say that iboga provides holistic healing. Main Takeaway.

Treatment 98

Treatment Medicine Research and Development Therapy 98

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. One such alternative treatment is cannabis.

Patients 52

Patients Treatment Therapy Sleep 52

Veriheal

JANUARY 26, 2023

Most commonly, pharmaceutical medication is prescribed to regulate moods. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients. Thus, this groundbreaking study laid the foundation for understanding how cannabinoids can support mental health.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy.

Access 52

Access Patients Research and Development Treatment 52

The Joint Blog

NOVEMBER 2, 2020

According to a new study published in the Journal of Pharmacy & Pharmaceutical Sciences, using marijuana as an adjunct treatment for Huntington disease (HD) is both effective and safe. The study states that marijuana can improve neurological symptoms and should be recommended to HD patients by their physicians.

Treatment 37

Treatment Sleep Marijuana Patients 37

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

JUNE 19, 2023

The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons. All the data provided by the report are validated and trustworthy and can be used to gain the upper hand in the industry. billion in the next six years.

Therapy 109

Therapy Treatment Patients Policy 109

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

CannaMD

NOVEMBER 22, 2020

Unfortunately, most traditional pharmaceutical options are distinctly lacking due to side effects, as well as a bit of trepidation (although Botox, one current treatment option for migraines, has gained popularity). Patients used the app, Strainprint, which allowed data to be archived and studied.

Marijuana 116

Marijuana Treatment Patients Cannabinoids 116

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. Promising research in psychedelics as a mental health treatment accelerates growth of industry in need of legal counsel.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. In 2019, the island’s economy grew by 2.1% in real terms to £4.97 to reach 3.2

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. World Health Organization (WHO).

THC 59

THC Clinical Trials Data Consumption 59

Cannabis Law Report

JULY 12, 2021

Algernon Pharmaceuticals Inc. CSE: MSET) revealed additional preclinical data showing strong efficacy and improved safety in a head-to-head comparison with psilocybin. (CSE: PULL). 0.385 +0.155 (67.39%). Cybin Corp. NEO: CYBN). 3.250 +0.650 (25.00%). Numinus Wellness Inc. TSX-V: NUMI). 1.020 +0.110 (12.09%). Top Decliners. CSE: TMED).

Treatment 66

Treatment Decriminalization Pharmaceutical Data 66

Veriheal

OCTOBER 29, 2020

Is the focus on the negative impact due to the fact that role players want cannabis to remain illicit as to avoid its potential role in replacing pharmaceutical medication? The data for this graphic was provided by Jim Hudson at Hellth.com. . Scenario 2: Pharmaceuticals. However, the focus of funding remains on negative impacts.

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

United Patients Group

MAY 17, 2023

Recently, a pharmaceutical company has created a cannabis based isolate, meaning one cannabinoid, in this case CBD called Epidiolex which is available by prescription in all 50 states. Some ASD patients still feel that some THC is needed to truly experience the benefits of whole plant medicine in the treatment of ASD.

Sleep 78

Sleep Cannabinoids Patients CBD 78

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

CannaMD

JULY 23, 2020

In the novel study conducted by researchers at the University of New Mexico, nearly 2,000 people self-administered cannabis over a three-year period and reported their marijuana use via the Releaf App that was specifically designed for the study’s data collection needs. THC VS. CBD.

Data 90

Data Chronic Pain Sleep Patients 90

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. A 2019 study found that 76% of patients in the U.S. fill an opioid prescription after having surgery compared to just 11% of Swedish patients.

Programs 52

Programs Chronic Pain Treatment Conditions 52

PrestoDoctor

SEPTEMBER 6, 2023

It has been a go-to option for healthcare professionals seeking to manage pain effectively for their patients. This has led many patients to explore cannabis as a potential substitute for prescription codeine. Additionally, common side effects such as drowsiness, constipation, and respiratory depression can be burdensome for patients.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105